Asymptomatic hyperparathyroidism reveals negative relationship between PTH, trabecular bone score
Click Here to Manage Email Alerts
Patients with normocalcemic hyperparathyroidism and those with hypercalcemic hyperparathyroidism have similar trabecular bone scores, according to study findings published in Endocrine Practice.
Researchers noted that a decrease in trabecular bone score was found among patients with asymptomatic hyperparathyroidism related to parathyroid hormone (PTH) levels, but there was no effect on bone mass.
Jose Luis Perez-Castrillón, MD, PhD, of the Hospital Universitario Río Hortega de Valladolid in Spain, and colleagues evaluated 39 patients with asymptomatic hyperparathyroidism and 24 controls with normal serum calcium and PTH levels to determine differences in trabecular bone scores. Participants with hyperparathyroidism were divided into two groups: normocalcemic (n = 24) and hypercalcemic (n = 15).
Trabecular bone score and areal bone mineral density were similar among participants in both hyperparathyroidism groups.
Compared with controls, participants with asymptomatic hyperparathyroidism had higher PTH (P < .0001) and total serum calcium levels (P = .013) and lower BMD at the spine (P = .04), femoral neck (P = .001) and total hip (P = .01). No controls were classified as having osteoporosis compared with 31% of the asymptomatic hyperparathyroidism participants.
Those with asymptomatic hyperparathyroidism had an inverse relationship between PTH and trabecular bone score (P = .043).
“There was no difference in the [trabecular bone score] between [normocalcemic] and [hypercalcemic hyperparathyroidism] patients,” the researchers wrote. “However, there was a reduction in the [trabecular bone score] in patients with asymptomatic [hyperparathyroidism] that was possibly related to the PTH levels but had repercussion on bone mass. Higher levels of PTH seem to be responsible for this alteration in microarchitecture texture.” – by Amber Cox
Disclosure: The researchers report no relevant financial disclosures.